KR101495991B1 - Compositions comprising spent turmeric for appetite suppression, and preventing or treating obesity - Google Patents

Abstract

The present invention relates to a composition for prevention or treatment of appetite suppression and metabolic diseases associated with obesity, which comprises an extract of Ulgum with curcumin removed from Ulgum. Specifically, the composition of the present invention is useful for preventing, treating and improving obesity-related metabolic diseases such as stroke, hyperlipidemia, arteriosclerosis, cardiovascular disease and non-alcoholic fatty liver caused by appetite suppression and obesity . ≪ / RTI >

Description

[0001] The present invention relates to a composition for preventing or treating appetite suppression and obesity,

The present invention relates to a composition for the prevention or treatment of appetite suppression and obesity d, which comprises a uremic residue obtained by removing curcumin from Ulmus.

Today, society is becoming a world that enjoys convenience according to industrialization and automation, but with a rapid social change, various diseases related to lifestyle diseases are increasing. In particular, obesity is increasing due to abnormal lipid metabolism and energy imbalance due to excessive intake of high calorie foods and lack of exercise depending on the Westernized diet. Thus, obesity refers to a state in which energy intake over a long period of time exceeds consumption and excess energy is converted to triglycerides and chronic accumulation in the subcutaneous and abdominal regions. According to a 2006 World Health Organization (WHO) report, overweight and obesity among the world's over 15-year-old population is growing to about 1.6 billion and about 400 million, respectively. By 2015, Billion people will become overweight and obesity population is expected to reach more than 700 million people.

Obesity is known to be a risk factor for increasing the incidence of neurodegenerative diseases such as diabetes, cardiovascular disorders, obstructive sleep apnea, stroke, cancer as well as Parkinson's disease and Alzheimer's disease (Kopleman., Nature, 404, 2000; Manson et al., New England J. Med., 333, 1995; Must et al., JAMA, 282, 1999). In addition, chronic inflammation and oxidative stress resulting from obesity have been found to exacerbate obesity and obesity-related metabolic diseases (Das UN, Nutrition, 2001; 17; 11-12: 953-966).

Neutral fat stored in fat cells is used as an important energy source in the body. However, as obesity progresses, the differentiation of adipocytes leads to an increase in lipoprotein and cell size. Depending on the amount of fat stored, the diameter of the adipocyte may increase up to 20 times, resulting in a cell volume of up to several thousand times .

Obesity patients have increased levels of inflammatory cytokines such as TNF-α, IL-6 (interleukin-6), and MCP-1 (monocyte chemoattractant protein-1) in the blood. These inflammatory cytokines, also called adipocytokines, are secreted as the size of adipocytes increases and are known to cause chronic inflammation and worsen insulin resistance as obesity progresses (Charriere et al. , J. Biol. Chem., 278, 2003). Therefore, it is important to adjust the fat catcher and size in order to improve the obesity status. The size of adipocytes can be regulated through diet and exercise therapy, but since the increased number of cells is ineffective as a dietary regulator, to control the underlying treatment or inhibition of obesity-related diseases, It is important to control the differentiation process.

In order to effectively treat the obesity caused by various causes and effects, drug development research is proceeding with the following development strategies. The first is to induce heat decomposition in the adipocyte to induce the degradation of fat, and the second is to inhibit the lipase action of the fat, which is a lipase, to reduce the absorption of fat. The third is to control obesity by controlling dietary intake and energy consumption, and in particular, drugs that block central nervous system neurotransmitters that act on the hypothalamus and brainstem (Dr. Korean J Pediatr 48, 2005).

Recently, the role of gastrointestinal hormones has also been recognized as a target of obesity treatment. Specifically, nutrients entering the stomach stimulate gastrointestinal hormone secretion. These hormones activate the vagus nerve, an afferent nerve to the brainstem, increase secretion of the appetite suppressing peptide in the hypothalamus, and cause anorexia Peptides such as orexin and melanin, which stimulate the secretion of the peptide thyrotropin-releasing hormone (TRH), oxytocin, and corticotrophin-releasing hormone (CRH) It decreases the production of hormone (melanin-concentrating hormone, MRH). In other words, when the satiety signals from the gastrointestinal tract are transmitted to the hypothalamus via the vagus nerve, anorexia will occur. In particular, glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), hormones secreted from the small intestine and large intestine L cells, play an important role in controlling glucose, triglyceride and appetite.

Some of the most popular anti-obesity drugs currently on the market include Xenical ^™ (Roche Pharmaceuticals, Switzerland), Reductil ^™ (Abbott, USA), Exolise ^™ (Atopama, France). However, among these synthetic therapies, central nervous system drugs (reductil) are associated with side effects such as heart disease, respiratory disease, and neurological diseases, and their persistence is low. Therefore, Research and development is required.

Curcuma longa L. is a perennial herb that belongs to the genus Zingiberaceae. It is native to tropical Asia and is cultivated in Jeollanamdo in Korea. It has been reported that curcuminoids such as curcumin, bisdemethoxycurcumin and demethoxycurcumin, turmerone, cineol, flavonoids, ), Essential oils such as coriander, starch and dietary fiber as saccharides. Studies on the physiological activities such as bile secretion promotion, antibacterial effect, liver function improvement effect, blood cholesterol improvement effect, antioxidant effect, whitening effect and antidepressant effect have been reported as the pharmacological effects of curcumin, In recent years, studies have been made on compositions useful for inhibiting appetite and improving obesity-related metabolism by using a herbal extract as the prevention effect of weight gain by inhibiting the differentiation of adipocytes as well as the neutral lipid-lowering function in the blood.

In this connection, Korean Patent Publication No. 2012-0002131 discloses a composition relating to an appetite suppressant and an obesity-related metabolism improving composition containing ugum, and discloses a composition for treating or preventing obesity, 2011-0054327 discloses a health functional food composition for preventing or ameliorating obesity containing C. zedoaria extract and Korean Patent Publication No. 2010-0114266 discloses a composition for prevention of weight gain and reduction of blood neutrality quality ≪ / RTI > is disclosed for a dietary composition containing a wool methanol extract. Japanese Laid-Open Patent Application No. 1999-193240 also discloses a composition for improving lipid metabolism, which comprises Cariomatica .

However, most of the studies and patents related to the above-mentioned improvement of appetite suppression and improvement of metabolism related to obesity are based on extracts containing curcumin or curcumin. In addition, despite the pharmacological effects of curcumin, which is the main component of Ulgum, the characteristic odor and bitter taste of Ulgum influenced consumers' preferences, making it difficult to utilize them industrially. In order to maximize the efficacy of curcumin, optimal extraction technology is insufficient. In this study, we tried to eliminate the bitter taste and odor of Ulgum by mixing fermented Ulgum Extract with other natural herbs, fermentation using Bacillus subtilis, and mixed fermentation of brown sugar and black germ. Research has been carried out on increasing absorption, minimizing side effects and allergic reactions, and establishing optimal extraction technology of curcumin.

Since non-digesitible carbohydrates including dietary fiber are not degraded by human digestive enzymes, they are fermented by microorganisms in the intestines to produce short-chain fatty acids, which are fermented products, They act as prebiotics that inhibit the growth of harmful bacteria. Such indigestible saccharides are widely known to improve the intestinal environment and improve hyperlipemia and the like. Recent studies have shown that inulin, a soluble dietary fiber, is known to promote gastrointestinal hormone, GLP-1 and PYY secretion, and is expected to inhibit appetite and improve diabetes and metabolic syndrome. In addition, short-chain fatty acids, which are fermented products, are attracting attention as a central factor of metabolism. Therefore, it is known that non-bioactive dietary fibers such as cellulose have no prebiotics effect. On the other hand, Ulgum has a high level of phosphorus-containing starch which is similar to dietary fiber and potato starch of about 20%, and is an obesity-related saccharide. It is related to obesity such as appetite suppression, body fat reduction, blood lipid reduction, It is expected to contribute to the improvement of metabolic disorders. However, there is a problem in that when a large amount of Ulgum is consumed, the curcumin decreases the absorption of the body, thereby exerting a strong antimicrobial effect in the intestines, thereby breaking the balance between various microorganisms and causing various intestinal diseases (Bhavanishanker and Murthy, Food Microbiology, 1986).

Therefore, the inventors of the present invention have focused on the extract of curcumin, which has been extracted from curd curd and used as a livestock feed or an industrial waste, and found that the curd residue of curd curd refuse and the prevention and treatment of obesity related metabolic diseases As a result of efforts to develop a composition, the present invention has been completed.

It is an object of the present invention to provide a composition for prevention or treatment of appetite suppression and obesity-related metabolic diseases, which comprises the extract of Ulgum with curcumin removed.

Another object of the present invention is to provide a functional food composition for preventing or ameliorating an appetite suppressing and obesity-related metabolic diseases, which comprises a urea residue obtained by removing curcumin from Ulgum.

It is another object of the present invention to provide a pharmaceutical composition for prevention or treatment of appetite suppression and obesity-related metabolic diseases, which comprises Ureum residue removed from curcumin of Ulmus.

The present invention provides a composition for prevention or treatment of appetite suppression and metabolic diseases associated with obesity, which comprises a Uleum residue obtained by removing curcumin from Uleum.

The Curcuma longa L. of the present invention is a perennial plant belonging to the genus Ginger. It is preferred that the gilts used in the present invention are used in the form of a turmeric which is washed, cut and dried after pulp roots to facilitate the removal of curcumin.

As used herein, the term " appetite suppression " means any action that inhibits or delays appetite by promoting the secretion of dietary hormones by administration of the composition.

As used herein, the term " obesity-related metabolic disease " refers to a disease caused by excessive lipid accumulation in the body and refers to obesity and diseases caused by it. The diseases caused by obesity include, for example, stroke, hyperlipidemia, arteriosclerosis, cardiovascular disease, and non-alcoholic fatty liver.

As used herein, the term " prophylactic " refers to any act that inhibits or delays the onset of an obesity-related metabolic disorder upon administration of the composition. The term " improvement or treatment " used in the present invention means all actions in which excess body fat caused by metabolic diseases associated with obesity is reduced or changed by administration of the composition.

In the present invention, the spent turmeric removed from the curcumin of the Korean Penaeus is a substance obtained by removing curcumin from the Korean curry using an organic solvent and filtering the same. Such enamel residues include both by themselves or by powdering them.

The organic solvent may be selected from the group consisting of methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethylsulfoxide , 3-butylene glycol, propylene glycol or a mixed solvent thereof, preferably methanol and ethanol, and more preferably ethanol.

As a specific example, 300 to 600 parts by weight of 99% ethanol may be added to 100 parts by weight of corn, and the mixture may be stirred for 2 to 10 hours at 25 ° C to 100 ° C, and filtration may be repeated three times. When the amount of the ethanol is less than 300 parts by weight or less than 25 캜, the curcumin of the urophyllactam is left without being completely removed, so that the reaction is required to be repeated six times or more. When the amount is more than 600 parts by weight or 100 캜, The efficiency is almost the same and is not economical.

The curcumin removal from the coryneform reagent with the organic solvent can be effected by separation or filtration. For example, particles may be filtered using a cotton, nylon, wattman paper or the like, or centrifugation may be used. In addition, it may further comprise a separation process by various chromatographies (size, charge, hydrophobicity or affinity chromatographic). In some cases, it is possible to add a step of drying and pulverizing the residue of curd with the curcumin removed, and the drying is not limited thereto including lyophilization, vacuum drying, hot air drying, spray drying, vacuum drying and the like.

According to the present invention, the ureum residue is a nutrient source of probiotics and helps improve the intestinal environment. Most of them contain a resistant starch or dietary fiber, and short-chain fatty acid ) To acidify the intestinal environment to activate obesity activity, inhibit fat absorption, reduce body fat content, and reduce triglyceride in blood to prevent and treat obesity-related metabolic diseases.

In one specific embodiment, it was confirmed that the body weight and the intake of the rats fed with the diet supplemented with the urea residue of the present invention were decreased in the high fat diet, and the fat content in the defecation and defecation was increased. In addition, it was found that the weight and size of fat tissue around the kidney, the testis, and the decrease of blood triglyceride and blood GLP-1 concentration were increased.

In the present invention, the composition can be used as a functional food composition for preventing and ameliorating appetite suppression and obesity-related metabolic diseases.

When used as the functional food composition, the composition may be composed of only a composition for preventing and treating appetite suppression and metabolic diseases related to obesity of the present invention, or may include food-acceptable food supplementary additives. The food-aid additive contained in the functional food composition of the present invention can be used as various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, ≪ / RTI > In addition, the food of the present invention may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination.

The functional food may be in the form of a capsule, a tablet, a powder, a granule, a liquid, a ring, a flake, a paste, a syrup, a gel, a jelly and a bar, but is not limited thereto.

The kind of the food is not particularly limited. Examples include dairy products including meats, sausages, breads, chocolates, snacks, confectionery, pizza, ramen noodles, other noodles, gums and ice cream, soups, beverages, tea, drinks, alcoholic beverages and vitamin complexes. Functional foods in the sense of being.

In the present invention, the composition can be used as a pharmaceutical composition for preventing and treating appetite suppression and metabolic diseases related to obesity.

The pharmaceutical composition may include pharmaceutically acceptable carriers, excipients and diluents in addition to the composition for preventing and treating appetite suppression and obesity-related metabolic diseases of the present invention. The pharmaceutically acceptable carriers to be contained in the pharmaceutical composition of the present invention are those conventionally used in the present invention and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical composition may be applied by oral or parenteral administration to mammals such as rats, mice, livestock, humans, and the like, more preferably by oral administration.

The pharmaceutical composition is administered in a pharmaceutically effective amount. In the present invention, a pharmaceutically effective amount means an amount sufficient to treat or prevent a disease at a reasonable benefit / risk ratio applicable to medical treatment or prevention. The effective dose level will depend on the type of disease and its severity, Including the age, weight, health and sex of the patient, sensitivity of the patient to the drug, time of administration of the particular extract used, route of administration and rate of release, duration of treatment, Can be determined according to factors well known in the art. Generally, a dose of 0.1 to 100 mg / kg per day may be administered to an adult in one to several times a day.

The pharmaceutical composition may be prepared in the form of a unit dose by formulating it with a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by those having ordinary skill in the art to which the present invention belongs. Into a multi-dose container. The formulations may be formulated into tablets, capsules, powders, granules, suspensions, emulsions, syrups, emulsions and the like, which are customary in the pharmaceutical art depending on the purpose of the treatment.

According to the present invention, it is possible to increase the amount of short-chain fatty acids in the cecum of the rat by acidifying the intestinal environment, thereby increasing the amount of fat removed during defecation and defecation and increasing the body weight, body fat and dietary intake . In addition, the weight and size of adipose tissue, blood triglyceride content, and GLP-1 concentration are increased. Therefore, it is useful for functional foods and medicines for prevention, treatment and improvement of obesity-related metabolic diseases caused by appetite suppression and obesity.

FIG. 1 shows the results of measuring the weight gain and the appetite suppression effect of the Ulgum residue.
FIG. 2 shows the results of observing the decrease in the neutrophil quality in the blood of the fasted rats caused by the Ulgum residue.
FIG. 3 shows the results of observing the inhibition of differentiation of adipocyte-derived adipocytes by an urea residue by aldehyde-fuchsin staining.

Hereinafter, the present invention will be described in more detail with reference to examples. It is to be understood that these embodiments are provided by way of illustration only, and are not intended to limit the scope of the invention.

Example  One : Ulgum Curcumin  Removed Kool  Residue ( spent  turmeirc, no curcumin ) Powder manufacturing

2kg of Korean radish root (Korean) was collected and thoroughly cleaned to remove foreign matter and impurities, and moisture of the surface was removed. Then, it was cut at a constant size and then dried at 50 ° C for 8 hours and then pulverized to a particle size of 1 mm or less using a pulverizer. 1 kg of the urophyll powder was immersed in 6 liters of 99% ethanol and reacted at room temperature for 2 hours. The reaction was then filtered through a filter paper (Advantes, No. 2) to remove curcumin contained in the supernatant. After repeating the same operation three times, the curd residue was removed from the curd residue at a temperature of 40 ° C to prepare curd residue-free curd residue powder.

Comparative Example  One : Curcumin  included Turmeric powder ( turmeric ) Produce

2kg of fresh ugly root (Korean) was taken and cleaned thoroughly to remove impurities and impurities, and then cut to a certain size. Then, the water-removed corn was heated at 50 ° C. for 8 hours, and then pulverized to a size of 1 mm or less using a dried corn silk pulverizer.

Example  2 : Kool Residue  Powder and Kool  Comparison of general components of powders

The contents of moisture, fat, protein, ash, carbohydrate, dietary fiber, and curcumin were analyzed by AOAC general component analysis using the Ulgum residue powder and urogal powder obtained in Example 1 and Comparative Example 1. The results are shown in Table 1.

1) Moisture

5 g each of the urea residue powder and the urea powder obtained in Example 1 and Comparative Example 1 were dried in a vacuum oven at 105 캜 and dried for about 5 hours so that the weight was constant (pressurized warm drying method, AOAC method 926.08 and 925.09, 1990).

2) Fat

5 g of each of the urea residue powder and the urea powder obtained in Example 1 and Comparative Example 1 were mixed with a hydrochloric acid solution and hydrolyzed. The fat was then extracted with ether and hexane. The extract was washed with a dilute alkaline solution and then filtered through a sodium sulfate column. The filtered extract was evaporated, dried and weighed (acid decomposition method, AOAC method 922.06 and 954.02, 1990).

3) Protein

5 g each of the urea residue powder and the urea powder obtained in Example 1 and Comparative Example 1 were dissolved in ammonia containing sulfuric acid containing a mercury catalyst. The alkaline solution of the decomposed acid was distilled off and the ammonia was distilled off and titrated with standard acid. The nitrogen content was measured and the protein amount was calculated by multiplying by 6.25 (Kjeldahl method, AOAC method 955.04C and 979.09, 1990).

4) Ashes

5 g of each of the urea residue powder and the urea powder obtained in Example 1 and Comparative Example 1 were ignited at 550 캜 to remove volatile organic substances. The residue contents were weighed and the ash content was calculated (Direct Conversion, AOAC 923.03, 1990).

5) Carbohydrate

Using the above data of protein, fat, ash, and moisture content, the carbohydrate content was calculated by the following equation 1 (USDA Agricultural Handbook Volume 8, 1975).

[Equation 1]

Carbohydrate content (%) = 100 - (protein content + fat content + ash content + water content)

6) Dietary fiber

100 g of each of the urea residue powder and urogal powder obtained in Example 1 and Comparative Example 1 was degreased with an organic solvent, and then each sample was treated with an enzyme and proteolytic enzyme. After centrifugation, ethanol was added to the undissolved residues and stirred. Then, the residues obtained by alcohol precipitation and the supernatant were separated and dried, and their weights were measured. At this time, the total amount of the supernatant was calculated as the total dietary fiber as the soluble dietary fiber, the remaining water as the non-water soluble dietary fiber, and the total amount of the dietary fiber as the total dietary fiber (Prosky method, AOAC method 985.29 and 991.42 and 991.43 and 993.19, 1990).

7) Curcumin

5 g of the urogine powder obtained in Comparative Example 1 was added with 99% ethanol and stirred at 95 캜 for 3 minutes. Then, the mixture was centrifuged at 8000 x g for 10 minutes, and then filtered with a syringe filter (0.45 mu m). The mixture was concentrated using a rotary evaporator (Shibata Rotavapor, Japan), and finally dissolved at a concentration of 1 mg / ml using acetyl nitrile. HPLC (1200 Series, Agilent Technologie, USA) -Mass (spectrometer 6410, Agilent Technologies) The content of curcumin was analyzed. In order to measure the curcumin content remaining in the urea residue powder, 99% ethanol was added to 5 g of the urea residue powder obtained in Example 1 to obtain an extract. The extract was centrifuged at 8000 x g for 10 minutes, 0.45 mu m). The mixture was concentrated using a rotary evaporator (Shibata Rotavapor, Japan), and finally dissolved at a concentration of 1 mg / ml using acetyl nitrile. HPLC (1200 Series, Agilent Technologie, USA) -Mass (spectrometer 6410, Agilent Technologies) The content of curcumin was analyzed. The column used was Zorbax Eclipase C18 (30 mm × 2.1 mm, 3.5 μm, Agilent Technologies), the mobile phase was acetonitrile and 1 mM formic acid (70:30, v / v ) and the flow rate was 0.8 ml / min. During the analysis, (-) electrospray interface (ESI) conditions were: capillary voltage 72.5 kV, nebulizer 50 psi, collision energy 10 V, source temperature 80 ° C, gas temperature 300 ° C, cone gas flow 8 L / min, gas flow 8 L / min. The results are shown in Table 1.

(g / 100 g) Example 1 Comparative Example 1 moisture 10.7 10.8 protein 10.8 10.4 Fat 1.0 4.7 Ash 7.7 7.4 carbohydrate 69.8 66.7 Total dietary fiber 20.3 19.4 Soluble fiber 1.9 1.7 Insoluble dietary fiber 18.4 17.7 Curcumin <0 5.5

As shown in Table 1, it was confirmed that the dietary fiber of the urea residue and the urea obtained in Example 1 and Comparative Example 1 contained 19% or more of the total weight, and the most non-soluble dietary fiber was the most abundant. Also, the residual curcumin content of the urea residue obtained in Example 1 was detected to be below the detection limit, and the curcumin content of the urea obtained in Comparative Example 1 was about 5.5%.

Example  3: Experimental breeding and experimental animal breeding

Seven-week-old SD male rats (Charles River Japan, Japan) were preliminarily raised for one week and 18 were used for the experiment. The animals were housed in a thermostatic chamber set at a temperature of 23 ± 1 ° C., a humidity of 60 ± 5 ° C. and an illumination time of 12 hours / day. The diet was 49% high calorie diet based on AIN-93G diet and used as a control (CON) diet. CON group and STP group supplemented with 10% of dietary weight TP group supplemented with urogal powder instead of alpha starch powder or 10% UG powder were added to the three groups (6 per group) for 4 weeks 28 days). The composition of the diets of each group is shown in Table 2.

Constituent
(g / kg) Diet CON TP STP Casein 200 200 200 L-cystine 3 3 3 saccharose 100 100 100 RAD ¹ 230 230 230 Soybean oil ¹ 40 40 40 Tert-butylhydroquinone 0.054 0.054 0.054 cellulose 50 50 50 Comprehensive mineral (AIN-93G) 35 35 35 Multivitamin (AIN-93G) 10 10 10 Hydrogen stearate choline 2.5 2.5 2.5 Alpha-starch 100 - - Turmeric powder - 100 - Spent turmeric - - 100 Corn starch 229.446 229.446 229.446 Total (g) 1000 1000 1000 Calories (kcal / kg) ² 4958 4909 4889 ¹ 49.6 kcal%
² protein was 4 kcal / g, fat was 9 kcal / g, carbohydrate was 4 kcal / g, and dietary fiber calorie was calculated as 0 kcal / g.

Example  4: Dietary intake, weight gain measurement

Dietary intake of each group was measured daily and body weight was measured weekly for 4 weeks. The results are shown in Fig.

As a result, as shown in FIG. 1, the CON group fed with the high-fat diet had a large increase in body weight, but the TP group fed with the high fat diet mixed with the composition containing the urea powder and the urea residue powder And STP group were decreased in weight compared to CON group. Also, total dietary intake and intake energy of TP group and STP group were decreased compared to CON group.

Example  5: Fecal  Excretion, water content and fat content measurement

The feces were collected for 3 days after transferring the experimental animals to the dark room for the last 4 days during the experiment. The weight of the feces removed after the collection and the weight of the feces after lyophilization were measured and the difference between the two values was regarded as the water content. The lyophilized feces were homogenized to obtain a part, and lipids were extracted with a chloroform-methanol (2: 1, v / v) solvent and dried using a rotary condenser. (TEF-E-test), free fatty acids (NEFA HAII) and cholesterol (Cholesterol) were measured by using lipid analysis kit reagent (Wako, Japan) from the total lipids in the feces. E-test). The colorimetric values of triglyceride and total cholesterol were 600 nm and free fatty acids were measured at 550 nm using a spectrophotometer (Shimadzu UV-1600, Japan). The results are shown in Table 3.

Diet CON TP STP Fecal excretion (wet g / day) 2.50 0.06 ^b 3.84 ± 0.25 ^a 3.82 ± 0.24 ^a Fecal excretion rate ¹ (% / day) 11.2 ± 0.3 ^c 20.2 ± 0.6 ^a 17.4 ± 0.5 ^b Water content (%) 20.9 ± 1.0 ^b 29.0 ± 2.3 ^a 25.6 ± 2.0 ^ab Triglyceride (mg / day) 28.3 ± 3.1 ^a 42.2 ± 3.9 ^a 33.7 ± 4.7 ^a Triglyceride Emission Rate ² (%/Work) 0.433 + 0.050 ^b 0.833 + 0.057 ^a 0.571 + 0.067 ^b Free fatty acids (mg / day) 153 ± 16 ^b 223 ± 14 ^a 261 ± 17 ^a Free fatty acid emission rate ³ (%/Work) 2.38 ± 0.24 ^b 4.63 ± 0.19 ^a 4.47 ± 0.21 ^a Cholesterol (mg / day) 8.42 ± 0.85 ^a 9.10 ± 0.68 ^a 6.74 ± 0.60 ^a Values are mean ± standard error, n = 6, ^{a, b, c} Values with superscript are p values <0.05, using the tukey-HSD test.
A group with two characters overlapping means a group with no significant difference between any two groups.
¹ Daily fecal discharge (g) / daily intake (g).
² daily triglyceride emissions (g) / daily fat intake (g).
³ Emissions of free fatty acids per day (g) / daily fat intake (g).

As shown in Table 3, the fecal excretion amount and the fat content in the feces of the TP group and the STP group fed with the high fat diet mixed with the composition containing the urea powder and the urea residue powder were higher than that of the CON group fed with the high fat diet .

Example  6: Analysis of serum components

Blood was collected from the jugular vein of the rat fasted for 12 hours on days 0, 7, and 27 during the 4-week (28-day) experimental period. Blood was collected in a serum separation tube (Becton Dickinson, USA) and centrifuged at 8,000 rpm for 20 minutes to separate the serum and stored frozen at -80 ° C until analysis. Neutral fat was measured using an automatic blood analyzer (TBA-120FR autoanalyzer, Toshiba Medical Systems, Japan). The results are shown in Fig.

As a result, the TP group and the STP group fed with the high fat diet mixed with the composition containing the urogen powder and the urea residue powder showed a decrease in the serum triglyceride as compared with the CON group fed only with the high fat graft.

On the last day of the experiment (day 28), the animals were anesthetized with 4 mg of Nembutal (Abbott Laboratories, USA) per 100 g of body weight without fasting, and blood was collected. The blood was collected from the abdominal aorta. Blood was collected in a serum separation tube (Becton Dickinson, USA), centrifuged at 8,000 rpm for 20 minutes to separate the serum, and stored frozen at -80 ° C until analysis. Serum Lipid levels were measured by using TG-E-test, free fatty acid (NEFA HA II) and cholesterol E-test using lipid analysis kit reagent (Wako, Japan). The colorimetric values of triglyceride and total cholesterol were 600 nm and free fatty acids were measured at 550 nm using a spectrophotometer (Shimadzu UV-1600, Japan). Serum glucose concentration was measured with a spectrophotometer (Shimadzu UV-1600, Japan) at 570 nm using an assay kit reagent (LabAssayTM Glucose, Wako, Japan). GLP-1 was prepared by adding 20 μl of dipeptidyl peptidase-Ⅳ (DPP-IV) inhibitor per ml of blood at the time of blood collection and then using REBIS GLP-1 (active, Shibayagi, Japan) . The results are shown in Table 4.

Diet CON TP STP Total cholesterol (mmol / l) 1.87 + 0.07 ^b 2.28 0.08 ^a 1.86 ± 0.05 ^b Neutral fat (mmol / l) 2.81 ± 0.25 ^a 1.82 + 0.25 ^a 2.11 + - 0.35 ^a Free fatty acids (mEq / l) 4.02 + 0.41 ^a 2.33 ± 0.15 ^b 2.34 ± 0.24 ^b Glucose (mg / ml) 252 ± 11 ^a 206 ± 11 ^b 252 ± 4 ^a GLP-1 (pg / ml) 2.38 ± 0.24 ^b 4.63 ± 0.19 ^a 4.47 ± 0.21 ^a Values are mean ± standard error, n = 6, ^{a, b, c} Values with superscript are p values <0.05, using the tukey-HSD test.

As shown in Table 4, the TP group and the STP group fed with the high fat diet mixed with the composition containing the urogal powder and the urea residue powder showed a decrease in serum triglyceride and free fatty acid compared to the CON group fed only with high fat graft , And GLP-1 levels in serum, which is a dietary inhibitory hormone, were increased.

Example  7: The contents of the appendix pH  , Short chain  Fatty acids and Corruption  Measure

The cecum was excised from the blood sample of the Example 6, weighed, immediately frozen with liquid nitrogen, and stored frozen at -80 ° C. until analysis.

To measure the pH of the contents of the cecum, the sample stored at -80 ° C was thawed at the refrigeration temperature, 0.5 g of the contents of the cecum were collected, and diluted with 10 times of distilled water. The pH value was measured with a pH meter (Istek, 725P, ) Was used to measure the pH.

In order to measure short-chain fatty acids (acetic acid, propionic acid, butyric acid), the above samples were centrifuged at 10,000 rpm for 10 minutes. The resulting supernatant was transferred to a separate test tube, and 70% perchloric acid was added thereto. The mixture was stirred and centrifuged at 10,000 rpm for 30 minutes. The supernatant was filtered through a 0.45 μm filter (Tosho, Japan) And analyzed by HPLC (LC-10AD, Shimadzu, Japan). RSpak (KC-811, 8.0 mm x 300 mm, Shodex, Japan) was used as the HPLC column. In the mobile phase, 15 mM Na ₂ HPO ₄ containing 3 mM perchloric acid solution and 0.2 mM bromothymol blue was measured at an absorbance of 455 nm at flow rates of 0.7 ml / min and 1.2 ml / min, respectively.

To measure ammonia nitrogen, which is a decay product of the contents of the cecum, the supernatant obtained for measuring the short chain fatty acid was transferred to a separate test tube and diluted 50 times with 0.1 M phosphate buffer (pH 5.5) Ammonia-test, Wako, Japan) at 630 nm using a spectrophotometer (Shimadzu UV-1600, Japan).

In order to measure scatole, which is an odor component of the contents of the cecum, 3 ml of the supernatant obtained in order to measure the short chain fatty acid and 15 ml of a coloring reagent (para-dimethylaminobenzaldehyde) were reacted at room temperature for 20 minutes, For 10 minutes, and then the supernatant was measured at 568 nm using a spectrophotometer (Shimadzu UV-1600, Japan). To measure indole, another odor component, the supernatant obtained for measuring the short chain fatty acid was diluted with 2M Tris hydrochloric acid buffer, and 2 ml of sample and 2 ml of color development reagent (para-dimethylaminobenzaldehyde) were added to 20 After centrifugation at 3,000 rpm for 10 minutes, the supernatant was measured at 568 nm using a spectrophotometer (Shimadzu UV-1600, Japan). The results are shown in Table 5.

Diet CON TP STP Cecum Weight (g) 3.39 ± 0.21 ^a 4.23 ± 0.45 ^a 3.95 + - 0.23 ^a Apparent weight of contents (g) 2.44 ± 0.16 ^a 3.22 ± 0.41 ^a 2.99 ± 0.18 ^a Cecal sheath weight (g) 0.95 + 0.05 ^a 1.01 0.07 ^a 0.95 + 0.06 ^a PH in cecum 7.20 ± 0.03 ^a 6.79 + 0.04 ^b 6.85 ± 0.08 ^b Total short-chain fatty acids (μmol) 188 ± 18 ^b 371 ± 20 ^a 366 ± 24 ^a Acetic acid (μmol) 157 ± 14 ^b 293 ± 17 ^a 262 ± 25 ^a Propionic acid (μmol) 21.3 ± 2.7 ^b 36.9 ± 3.8 ^ab 40.0 ± 5.3 ^a Nitric acid (μmol) 10.0 + - 2.5 ^c 40.6 + 4.9 ^b 63.6 ± 6.8 ^a Succinic acid (μmol) 7.0 ± 1.7 ^b 23.8 ± 7.3 ^ab 46.4 + - 10.0 ^a Lactic acid (μmol) 82.9 ± 7.3 ^a 41.4 ± 7.9 ^ab 21.0 ± 9.0 ^b Ammonia nitrogen (mg) 1.28 ± 0.12 ^ab 1.56 ± 0.11 ^a 1.02 + - 0.14 ^b Scallol (μg) 0.84 + 0.11 ^b 5.50 +/- 0.76 ^a 1.03 + - 0.12 ^b Indole (μg) 0.31 ± 0.05 ^b 2.37 ± 0.35 ^a 0.31 0.03 ^b Values were mean ± standard error, n = 5, ^{a, b, c} Values with superscript were tested for significance using the Turkish multiple test method (tukey-HSD test) at p <0.05 level.
A group with two characters overlapping means a group with no significant difference between any two groups.

As shown in Table 5, it was confirmed that the intramuscular short-chain fatty acids of the TP group and the STP group fed with the high-fat dietary mixture containing the composition containing the urogulin powder and the urea residue powder were increased compared to the CON group fed only with the high fat graft . In addition, ammonia nitrogen as a decay component, indole and scallol as an odor component increased only in TP group, and STP group showed similar concentration to that of control group.

Example  8: Histopathological observation of visceral fat

Visceral adipose tissue (adipose tissue fat, fat around the kidney) was extracted from the rat in which blood was collected in Example 6, and the weight was measured. After weighing, some of the fat around the kidney was cut and stagnated in 10% buffer formalin. After fixation on paraffin, the adipose tissue was cut into 5 ㎛ using a microtome (Reichert-Jung 2050, ALT, USA), stained with aldehyde-fuchsin staining method, and microscopically observed Respectively. The results are shown in Table 6 and FIG.

CON TP STP Fat around the kidney (g) 18.6 ± 0.6 ^a 8.80 + - 0.84 ^c 12.5 ± 1.2 ^b Peritoneal fats (g) 15.3 + 1.0 ^a 7.57 + - 0.44 ^c 10.1 ± 0.4 ^b Fat (g) 33.9 ± 1.3 ^a 16.4 ± 1.2 ^c 22.7 ± 1.4 ^b Fat Size (μm ² ) 6956 ± 167 ^a 4586 ± 336 ^b 4883 ± 265 ^b Values were mean ± standard deviation, n = 6, ^{a, b, c} Values with superscript were tested for significance using the tukey-HSD test at p <0.05.

As shown in Table 6, the weight and fat size of visceral visceral fat (peripheral fat of the kidney and surrounding fat of the testicular body) and lipid size were measured using a TP Group and STP group were lower than those of CON group only.

In addition, as can be seen from FIG. 3, intracellular lipid accumulation in the kidney peripheral adipose tissue of the TP group and the STP group fed with the high fat diet mixed with the composition containing the urogen powder or the uremic remnant Compared to the CON group fed.

Claims (7)

A functional food composition for preventing or ameliorating an appetite suppressing and obesity, which comprises a uremic residue obtained by removing curcumin from Ulgum.
The functional food composition according to claim 1, wherein the curd residue of curd is removed by separating or filtering the curd curd from curd using an organic solvent.
[3] The functional food composition according to claim 2, wherein the urea residue is obtained by adding 300 to 600 parts by weight of ethanol to 100 parts by weight of corn glue, and removing the curcumin from the corn glue by separation or filtration.
delete A pharmaceutical composition for the prevention or treatment of appetite suppression and obesity, which comprises an extract of Ulgum with the removal of curcumin of Ulgum.
delete [Claim 6] The pharmaceutical composition according to claim 5, wherein 300 mg to 600 parts by weight of ethanol is added to 100 parts by weight of corn glue, and curcumin is removed from the corn glue by separation or filtration.

Images